B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study Group (DSHNHL) was founded in 1993 and has since conducted more than 25 national and international trials including more than 8000 patients in first line and salvage therapies. The DSHNHL is a network of haematooncologists, pathologists, radiologists, radiotherapists, nuclear physicians, biologists, geneticists and biometricians. All results of clinical trials performed by the DSHNHL were published in international journals and could lead a contribution to improve the treatment results.
Universitätsklinikum Münster; Medizinische Klinik A; Albert-Schweitzer-Campus 1, Gebäude A1; 48149 Münster
IMISE, Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig